1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with sipatrigine in 1 studies
| Studies (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Trials (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Recent Studies (post-2010) (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Studies (sipatrigine) | Trials (sipatrigine) | Recent Studies (post-2010) (sipatrigine) |
|---|---|---|---|---|---|
| 9,156 | 187 | 552 | 54 | 5 | 11 |
| Protein | Taxonomy | 1-hexadecyl-2-acetyl-glycero-3-phosphocholine (IC50) | sipatrigine (IC50) |
|---|---|---|---|
| Potassium channel subfamily K member 2 | Homo sapiens (human) | 4 | |
| Sodium channel protein type 2 subunit alpha | Rattus norvegicus (Norway rat) | 2.55 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alp, MS; Aspey, BS; Harrison, MJ; Patel, Y | 1 |
1 review(s) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and sipatrigine
| Article | Year |
|---|---|
Effects of combined glutamate and platelet-activating factor inhibition on the outcome of focal cerebral ischaemia - an initial screening study.
Topics: Animals; Brain Ischemia; Cerebral Infarction; Drug Combinations; Glutamic Acid; Leucine; Male; Movement Disorders; Neuroprotective Agents; Periaqueductal Gray; Piperazines; Platelet Activating Factor; Platelet Membrane Glycoproteins; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Sodium Channel Blockers; Time Factors | 1997 |